Skip to main content

Table 2 Reasonable and unreasonable omissions of drugs used during the study period

From: Implementation of clinical audit to improve adherence to guideline-recommended therapy in acute coronary syndrome

Months Not prescribed Total no.
Reasonable omissions
n (%)
Unreasonable omissions
n (%)
DAPT STATIN ACEI/ARB BB DAPT STATIN ACE-I/ARB BB
1 2 (2.4) 0 1 (1.6) 7 (8.1) 1 (1.2) 0 14 (17) 11 (14) 81
2 2 (3) 0 6 (7.6) 5 (6.08) 1 (1.3) 0 4 (5.2) 10 (13) 76
3 5 (5.6) 0 9 (9.4) 10 (10.3) 0 0 8 (9) 7 (7.4) 94
4 3 (3.2) 0 4 (4.5) 10 (12.3) 0 0 6 (7.3) 7 (9) 82
5 9 (9.6) 0 8 (7.9) 8 (8.8) 0 0 6 (6.2) 7 (7.2) 96
6 4 (4.9) 0 2 (2.4) 4 (4.9) 0 0 6 (7.2) 6 (7.2) 83
7 6 (7.6) 0 5 (6.4) 4 (5.3) 0 0 6 (8) 6 (8) 76
8 9 (12.5) 1 (1.4) 5 (6.6) 4 (5.1) 0 0 5 (7) 4 (5.4) 74
9 10 (11.7) 0 6 (7.5) 6 (4.2) 0 0 5 (6) 2 (2.3) 84
10 8 (7.9) 0 6 (5.9) 8 (7.7) 0 0 0 2 (2) 99
11 11 (11.7) 0 5 (4.9) 8 (7.8) 0 0 0 0 98
12 0 4 (4) 6 (6.1) 2 (2) 0 0 0 0 102
Significance P < 0.000 P < 0.000 P < 0.000 P < 0.000  
  1. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, DAPT dual antiplatelet therapy, BB beta-blocker, n number of patients